Compare, Analyse RANBAXY LAB (500359 | ) with SUN PHARMA (524715 | SUNPHARMA~EQ)
X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
 
Boost Trading
Profits in Four
Easy Steps
DOWNLOAD NOW!
  
Compare another company

  
  

RANBAXY LAB vs SUN PHARMA - Comparison Results

  
  

RANBAXY LAB 
  Change

Ranbaxy is India's top pharmaceutical company, manufacturing and marketing branded generic pharmaceuticals products and Active Pharmaceutical Ingredients. Ranbaxy's continued focus on US and European markets has helped it build deep product pipelines... More


SUN PHARMA 
Change
Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More
Stock Price Chart: ranbaxy lab Vs. sun pharma
Loading...
 
 
DO YOU LIKE THESE REPORTS? TELL US!
 Current Valuations
    RANBAXY LAB SUN PHARMA RANBAXY LAB/  
SUN PHARMA  
P/E (TTM) x -83.3 21.1 - View Chart
P/BV x 11.1 5.2 214.4% View Chart
Dividend Yield % 0.0 0.1 -  
 
 Financials
 RANBAXY LAB   SUN PHARMA
  EQUITY SHARE DATA
    RANBAXY LAB SUN PHARMA RANBAXY LAB/ 5-Yr Chart
    Mar-14 Mar-16 SUN PHARMA Click to enlarge
High Rs5251,201 43.7%   
Low Rs254706 36.0%   
Sales per share (Unadj.) Rs313.4117.5 266.8%  
Earnings per share (Unadj.) Rs-25.619.6 -130.8%  
Cash flow per share (Unadj.) Rs-14.423.8 -60.4%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.1 0.0%  
Book value per share (Unadj.) Rs78.0130.5 59.8%  
Shares outstanding (eoy) m423.322,406.60 17.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x1.28.1 15.3%   
Avg P/E ratio x-15.248.7 -31.2%  
P/CF ratio (eoy) x-27.140.1 -67.6%  
Price / Book Value ratio x5.07.3 68.3%  
Dividend payout %05.1 0.0%   
Avg Mkt Cap Rs m164,8832,294,813 7.2%   
No. of employees `00015.314.7 103.7%   
Total wages/salary Rs m25,77547,971 53.7%   
Avg. sales/employee Rs Th8,672.219,169.8 45.2%   
Avg. wages/employee Rs Th1,684.63,253.0 51.8%   
Avg. net profit/employee Rs Th-709.33,197.9 -22.2%   
 
  INCOME DATA
Net Sales Rs m132,685282,697 46.9%  
Other income Rs m1,8286,170 29.6%   
Total revenues Rs m134,513288,867 46.6%   
Gross profit Rs m9,73283,239 11.7%  
Depreciation Rs m4,76210,135 47.0%   
Interest Rs m5,5734,769 116.9%   
Profit before tax Rs m1,22674,505 1.6%   
Minority Interest Rs m20-11,126 -0.2%   
Prior Period Items Rs m-140-19 750.8%   
Extraordinary Inc (Exp) Rs m-8,643-6,852 126.1%   
Tax Rs m3,3149,349 35.5%   
Profit after tax Rs m-10,85247,159 -23.0%  
Gross profit margin %7.329.4 24.9%  
Effective tax rate %270.412.5 2,155.0%   
Net profit margin %-8.216.7 -49.0%  
 
  BALANCE SHEET DATA
Current assets Rs m70,357308,646 22.8%   
Current liabilities Rs m75,760132,477 57.2%   
Net working cap to sales %-4.162.3 -6.5%  
Current ratio x0.92.3 39.9%  
Inventory Days Days7683 91.6%  
Debtors Days Days5788 64.9%  
Net fixed assets Rs m53,839133,606 40.3%   
Share capital Rs m2,1172,407 87.9%   
"Free" reserves Rs m22,130266,909 8.3%   
Net worth Rs m33,031314,042 10.5%   
Long term debt Rs m24,74431,167 79.4%   
Total assets Rs m139,901542,196 25.8%  
Interest coverage x1.216.6 7.3%   
Debt to equity ratio x0.70.1 754.8%  
Sales to assets ratio x0.90.5 181.9%   
Return on assets %-3.89.6 -39.4%  
Return on equity %-32.915.0 -218.8%  
Return on capital %-3.417.8 -19.2%  
Exports to sales %27.614.0 197.2%   
Imports to sales %6.93.1 219.4%   
Exports (fob) Rs m36,62239,572 92.5%   
Imports (cif) Rs m9,1488,882 103.0%   
Fx inflow Rs m50,93942,171 120.8%   
Fx outflow Rs m23,50521,583 108.9%   
Net fx Rs m27,43420,588 133.3%   
 
  CASH FLOW
From Operations Rs m-35,62467,694 -52.6%  
From Investments Rs m18,320-44,549 -41.1%  
From Financial Activity Rs m10,162-19,243 -52.8%  
Net Cashflow Rs m-7,1433,902 -183.1%  
 
 Share Holding
Indian Promoters % 0.0 63.7 -  
Foreign collaborators % 63.4 0.0 -  
Indian inst/Mut Fund % 8.3 5.1 161.8%  
FIIs % 11.8 23.0 51.3%  
ADR/GDR % 1.5 0.0 -  
Free float % 15.0 8.3 180.7%  
Shareholders   182,721 133,026 137.4%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
Compare RANBAXY LAB With: JUBILANT LIFE SCIENCES | DR. DATSONS LABS | CADILA HEALTHCARE | GSK PHARMA | PANACEA BIOTECH
Compare RANBAXY LAB With: ADCOCK INGRAM (S. Africa) | MYLAN (US) | ACTAVIS (US) | TEVA PHARMA (Israel)


Today's Market

Sensex Finishes Flat; IT & Realty Stocks Close Strong(Closing)

Stock markets in India witnessed selling pressure in final hour of trade to finish flat amid mixed global markets. At the closing bell, the BSE Sensex stood higher by 28 points, while the NSE Nifty finished up by 13 points.

Related Views on News

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

Sun Pharma: US Segment Shows Signs of Improvement (Quarterly Results Update - Detailed)

Sep 12, 2016

Sun Pharma has announced its 1QFY17 results. The company has reported 22.7% YoY growth in sales and a growth of 266% in the net profits. Here is our analysis of the results.

Sun Pharma: Acquisition synergies start contributing (Quarterly Results Update - Detailed)

Apr 1, 2016

Sun Pharma has announced its 3QFY16 results. Net sales have grown by 2.3% YoY, while net profits surged by 258% YoY. Here is our analysis of the results.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Laurus Labs Ltd (IPO)

Dec 6, 2016

Equitymaster analyses Initial Public Offering (IPO) of Laurus Labs, one of the leading supplier of APIs for ARVs and Hepatitis C.

More Views on News

Most Popular

My Six Rules for Stock Picking(Outside View)

Feb 11, 2017

A wealth-building strategy is more than just about how to pick good stocks.

18.24% Gains in 19 Days... And I Am Still Disappointed(Daily Profit Hunter)

Feb 14, 2017

Apurva closed a trade with gains of 18.24% for his Swing Trader subscribers. But he's not happy about it. Find out why.

Think Twice Before 'Buying' the Buyback(The 5 Minute Wrapup)

Feb 21, 2017

Why buybacks may not always be a tempting proposition.

India's Ecommerce Ponzi Scheme Has Started to Unravel(Vivek Kaul's Diary)

Feb 15, 2017

The investors are writing down their investments in these firms.

TCS Has Maintained a High Payout(Chart Of The Day)

Feb 21, 2017

Will the proposed buyback change the fortunes of TCS?

More

RANBAXY LAB SHARE PRICE


Apr 1, 2015 (Close)

TRACK RANBAXY LAB

  • Track your investment in RANBAXY LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

RANBAXY LAB 8-QTR ANALYSIS

Detailed Quarterly Results With Charts

COMPARE RANBAXY LAB WITH

MARKET STATS